Research

Hormonal

GLP-1 receptor agonists provide cardiovascular protection through peripheral anti-inflammatory effects, independent of their weight-loss or glucose-lowering actions.

Beyond helping you lose weight, GLP-1 medications like semaglutide have been shown to protect your heart. This protection comes from reducing inflammation in your body's peripheral tissues, offering a dual benefit for metabolic and cardiovascular health.

GoodSupportsHIGH confidence
there is also strong evidence that GLP-1R ligands offer cardiovascular protection through actions in the periphery, including anti-inflammatory effects
Stefan Trapp et al. · British Journal of Pharmacology · 2022

Why this rating

Cites 'strong evidence' and a specific review (Helmstädter et al., 2021) on the topic.

Source

New developments in the prospects for GLP‐1 therapy

Stefan Trapp et al. · British Journal of Pharmacology · 2022

DOI 10.1111/bph.15788

narrative_reviewCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →